- Home
- NCPL vs SCNI Comparison
NCPL vs SCNI Comparison
Compare NCPL & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCPL
- SCNI
- Stock Information
- Founded
- NCPL 1984
- SCNI 2003
- Country
- NCPL United States
- SCNI Israel
- Employees
- NCPL N/A
- SCNI N/A
- Industry
- NCPL Investment Managers
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NCPL Finance
- SCNI Health Care
- Exchange
- NCPL Nasdaq
- SCNI Nasdaq
- Market Cap
- NCPL 3.4M
- SCNI 2.8M
- IPO Year
- NCPL N/A
- SCNI N/A
- Fundamental
- Price
- NCPL $1.88
- SCNI $3.40
- Analyst Decision
- NCPL
- SCNI
- Analyst Count
- NCPL 0
- SCNI 0
- Target Price
- NCPL N/A
- SCNI N/A
- AVG Volume (30 Days)
- NCPL 104.5K
- SCNI 5.6K
- Earning Date
- NCPL 03-21-2025
- SCNI 11-22-2024
- Dividend Yield
- NCPL N/A
- SCNI N/A
- EPS Growth
- NCPL N/A
- SCNI N/A
- EPS
- NCPL N/A
- SCNI 8.20
- Revenue
- NCPL $1,702,723.00
- SCNI $452,000.00
- Revenue This Year
- NCPL N/A
- SCNI N/A
- Revenue Next Year
- NCPL $101.16
- SCNI N/A
- P/E Ratio
- NCPL N/A
- SCNI $0.40
- Revenue Growth
- NCPL N/A
- SCNI N/A
- 52 Week Low
- NCPL $1.41
- SCNI $2.23
- 52 Week High
- NCPL $22.82
- SCNI $8.92
- Technical
- Relative Strength Index (RSI)
- NCPL 36.12
- SCNI 44.24
- Support Level
- NCPL $1.85
- SCNI $3.25
- Resistance Level
- NCPL $2.25
- SCNI $3.48
- Average True Range (ATR)
- NCPL 0.15
- SCNI 0.13
- MACD
- NCPL -0.05
- SCNI -0.01
- Stochastic Oscillator
- NCPL 5.45
- SCNI 17.39
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.